Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects
Source abstract
Abstract
IL-1α is closely related to the development and metastasis of cancer, and its polymorphisms have been reported affecting the susceptibility of malignancy tumors, yet the conclusions are controversial. Present an overall meta-analysis was performed to reach more general findings. Relevant literature was searched from Google Scholar, Web of Science, PubMed, EMBASE, CNKI database and Wanfang database, and the association among polymorphism and cancer risk was appraised by counting ORs and 95% CIs of overall and stratification analysis. The date from 15,586 cases and 18,430 controls in 40 publications were enrolled. There is significantly upregulated risk leads by rs3783553 in all genetic models, while the same tendency was found in all cancer types. The results also suggest a high risk of cancer susceptibility in patients carried rs1800587 polymorphism, of which draw out form allelic and homozygote models in overall studies, especially for cervical cancer. However, there are no significant results in analysis of rs17561. In a word, IL1A SNPs play an essential role in upregulating cancer susceptibility, and current analysis provides detail date for further study in the future.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune Cell Function and Interaction · Immune Response and Inflammation · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Urology, the First Affiliated Hospital of Anhui Medical University; Institute of Urology and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University
The First Clinical College of Anhui Medical University
Funding
National Natural Science Foundation of China
References (69)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.3322/caac.2155110.3322/caac.21551 ↗
3. 10.1111/imr.1262110.1111/imr.12621 ↗
4. 10.1111/imr.1261510.1111/imr.12615 ↗
5. 10.1038/s41590-018-0066-610.1038/s41590-018-0066-6 ↗
6. 10.1002/jso.2124510.1002/jso.21245 ↗
7. 10.1016/S0302-2838(03)00047-210.1016/S0302-2838(03)00047-2 ↗
8. 10.12659/MSM.89856910.12659/MSM.898569 ↗
9. 10.1016/j.ajpath.2015.07.00910.1016/j.ajpath.2015.07.009 ↗
10. 10.1002/jso.2153010.1002/jso.21530 ↗
11. 10.18632/oncotarget.324910.18632/oncotarget.3249 ↗
12. 10.2147/CMAR.S14769910.2147/CMAR.S147699 ↗
13. 10.3892/mmr.2012.101910.3892/mmr.2012.1019 ↗
14. 10.1007/s00251-007-0213-y10.1007/s00251-007-0213-y ↗
15. 10.1002/art.178038021010.1002/art.1780380210 ↗
16. 10.1007/s00251-002-0445-910.1007/s00251-002-0445-9 ↗
17. 10.1016/j.jclinepi.2009.06.00510.1016/j.jclinepi.2009.06.005 ↗
18. 10.1007/s10654-010-9491-z10.1007/s10654-010-9491-z ↗
19. 10.7326/0003-4819-127-9-199711010-0000810.7326/0003-4819-127-9-199711010-00008 ↗
20. 10.1016/0197-2456(86)90046-210.1016/0197-2456(86)90046-2 ↗
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959;22:719–748.
22. 10.1016/j.jtho.2018.01.02210.1016/j.jtho.2018.01.022 ↗
23. 10.1016/j.imbio.2015.09.01510.1016/j.imbio.2015.09.015 ↗
24. 10.1007/s12253-015-9941-810.1007/s12253-015-9941-8 ↗
25. 10.1016/j.ygyno.2004.08.02410.1016/j.ygyno.2004.08.024 ↗
26. Ai L, Shu Y. Association between interleukin- 1A polymorphisms and risk of glimoa. Chinese Journal of Laboratory Diagnosis 2014;18:1446–1448.
27. 10.1016/j.clinbiochem.2013.05.05010.1016/j.clinbiochem.2013.05.050 ↗
28. 10.1007/s10552-007-9082-910.1007/s10552-007-9082-9 ↗
29. 10.1186/1471-2407-8-38210.1186/1471-2407-8-382 ↗
30. 10.1002/hon.84310.1002/hon.843 ↗
31. 10.1093/carcin/bgl13010.1093/carcin/bgl130 ↗
32. 10.1080/1042819070161589210.1080/10428190701615892 ↗
33. 10.1016/S1470-2045(05)70434-410.1016/S1470-2045(05)70434-4 ↗
34. 10.1016/j.ygyno.2003.11.03910.1016/j.ygyno.2003.11.039 ↗
35. 10.1182/blood.V96.7.256210.1182/blood.V96.7.2562 ↗
36. 10.1007/s12032-012-0414-610.1007/s12032-012-0414-6 ↗
37. 10.1002/mc.2070610.1002/mc.20706 ↗
38. 10.1007/s13277-014-2123-610.1007/s13277-014-2123-6 ↗
39. 10.4317/medoral.16.e46710.4317/medoral.16.e467 ↗
40. 10.1111/j.1600-0714.2012.01162.x10.1111/j.1600-0714.2012.01162.x ↗
41. Snoussi K, Strosberg AD, Bouaouina N, et al. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. European Cytokine Network 2005; Dec16:253–260.
42. 10.1158/1078-0432.CCR-05-000110.1158/1078-0432.CCR-05-0001 ↗
43. Wang HM. Relationship between interleukin- 1 gene cluster gene polymorphisms and susceptibility to cervical cancer : Dalian Medical University; 2005.
44. 10.1016/j.ygyno.2006.10.01410.1016/j.ygyno.2006.10.014 ↗
45. Liao H, Zhang L, Chen P, et al. Insertion/Deletion Polymorphism of IL1A 3'- UTR Associated with the Susceptibility of Prostate Cancer. Journal of Sichuan University (Medical Science Education) 2014; 45: 956–959.
46. 10.1177/172460081878506910.1177/1724600818785069 ↗
47. 10.1002/jcb.2642710.1002/jcb.26427 ↗
48. 10.3233/CBM-16057410.3233/CBM-160574 ↗
49. 10.1111/jog.1298910.1111/jog.12989 ↗
50. Huang X, Yang Y, Cui ZW, et al. A functional insertion/deletion polymorphism in the IL1A gene is associated with decreased risk of breast cancer. Genet Mol Res. 2016;15: gmr7486.
51. 10.4238/2015.July.28.1710.4238/2015.July.28.17 ↗
52. 10.1016/j.ejca.2015.04.01610.1016/j.ejca.2015.04.016 ↗
53. 10.1089/gtmb.2015.001510.1089/gtmb.2015.0015 ↗
54. 10.1007/s11684-014-0326-210.1007/s11684-014-0326-2 ↗
55. 10.1016/j.humimm.2014.05.00410.1016/j.humimm.2014.05.004 ↗
56. 10.1007/s10689-014-9739-y10.1007/s10689-014-9739-y ↗
57. 10.1007/s13277-013-1512-610.1007/s13277-013-1512-6 ↗
58. 10.1007/s13277-013-1034-210.1007/s13277-013-1034-2 ↗
59. Sima XT, Liu H, Yang YW, et al. Association between an insertion/deletion polymorphism at miRNA- 122 binding site in the 3' untranslated region of interleukin- 1A and risk of glioma Chinese. Journal of Cancer Prevention and Treatment 2013;20:580–582.
60. He Y. Screening and Functional Analysis of Polymorphisms Residing in the MicroRNA Binding Sites of Hepatocellular Carcinoma- related Genes. Soochow University. 2010.
61. 10.1093/carcin/bgp28310.1093/carcin/bgp283 ↗
62. 10.1006/geno.1994.107610.1006/geno.1994.1076 ↗
63. Bailly S, Fay M, Israel N, et al. The transcription factor AP-1 binds to the human interleukin 1 alpha promoter. Eur Cytokine Netw. 1996; Apr-Jun7:125–128.
64. 10.1016/j.cyto.2004.12.01010.1016/j.cyto.2004.12.010 ↗
65. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Science Signaling. 2010;3:cm1.
66. 10.1016/j.ejcb.2010.04.00810.1016/j.ejcb.2010.04.008 ↗
67. Voronov E, Weinstein Y, Benharroch D, et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Research 1999; Mar 159:1029–1035.
68. 10.1093/carcin/bgn07310.1093/carcin/bgn073 ↗
69. 10.1093/nar/gkm48010.1093/nar/gkm480 ↗